Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
US-headquarted Synthetech, Inc., a fine chemicals company, specializes in organic synthesis, biocatalysis, and chiral technologies. Its products are used in the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at various stages of a customer’s clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular, and other diseases.
Synthetech engaged Bryan, Garnier & Co to conduct a comprehensive review of strategic alternatives aimed at enhancing shareholder value. Strategic alternatives it considered included the execution of its operating plan, the sale or acquisition of assets or businesses, partnering or other collaboration agreements or arrangements, a merger or sale of the company or other strategic transactions.
Grace is a leading global supplier of catalysts and other products to petroleum refiners; catalysts for the manufacture of plastics; silica-based engineered and specialty materials for a wide range of industrial applications; sealants and coatings for food and beverage packaging, and specialty chemicals, additives and building materials for commercial and residential construction. Founded in 1854, Grace has operations in over 40 countries.
As well as advising Synthetech on the sale, Bryan, Garnier & Co also issued a fairness opinion to the Special Committee of the Board of Directors of Synthetech.
The definitive merger agreement with Grace was announced on 14 September 2010 and delivered value for shareholders, with a significant premium over Synthetech’s recent trading range.
Grace acquired Synthetech from shareholders for an aggregate purchase price of USD19.2 million. Synthetech will be integrated into Grace Davison’s Specialty Technologies business and become a wholly owned Grace subsidiary.